Alexion's successor to Soliris hits co-primary endpoints in a pivotal, but can't surpass the big blockbuster
With a group of rivals pressing in from every side, looking to capture a piece of Alexion’s $ALXN blockbuster market for the rare disease trendsetter Soliris, researchers for the biotech say the first of two pivotal studies for PNH came through with non-inferior data on their next-gen drug dubbed ALXN1210. That should leave the company on track for a badly needed regulatory filing later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
